Pharming Group NV Sponsored ADR PHAR 深 沪

Pharming Group Balances Short-Term Strain With Pipeline Gains

Pharming Group N.V. (($NL:PHARM)) has held its Q1 earnings call. Read on for th...

05-08 09:23

Pharming Group shares are trading lower after the company reported worse-than-expected Q1 financial results.

Pharming Group shares are trading lower after the company reported worse-than-e...

05-07 20:52

Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M vs $421.375M Est

Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $405.000 million-$425.000 million to $405.000 million-$425.000 million vs $421.375 million estimate.

05-07 20:42

Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.

05-07 20:04

Pharming Projects FY2026 Total Revenues Of $405M-$425M With 8%-13% Growth Amid Pipeline Investments And Cost Reductions

For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million and US$335 million

05-07 14:02

Pharming Q1 EPS $(0.07) Misses $0.01 Estimate, Sales $72.400M Miss $93.750M Estimate

Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.01 by 800 percent. This is a 68.18 percent increase over losses of $(0.22) per share from the same

05-07 13:41

Pharming presents interim pediatric leniolisib extension study data in APDS at CIS 2026

Pharming presents interim pediatric leniolisib extension study data in APDS at CIS 2026 Pharming Group flagged new clinical readouts for leniolisib, with interim pediatric APDS outcomes slated for presentation at Clinical Immunology Society (CIS) 2026 in New Orleans during May 6-9. Disclosures will

05-07 13:14

Pharming presents leniolisib pediatric APDS data at Clinical Immunology Society meeting

Pharming presents leniolisib pediatric APDS data at Clinical Immunology Society meeting Pharming Group to present leniolisib data at Clinical Immunology Society 2026 Annual Meeting, scheduled May 6-9 in New Orleans. Program includes interim pediatric long-term extension results in APDS, plus clinica

05-07 13:14

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. announced multiple presentations at the 2026 Clinical Immunology Society (CIS) Annual Meeting, focusing on interim outcomes of a leniolisib extension study for pediatric APDS patients. Presentations also included data on leniolisib's use in treating immune dysregulation in CVID and CVID-like disorders, as well as insights into APDS and other primary immunodeficiencies. Two Phase II trials ...

05-07 05:05

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

04-23 06:00